Exposure–response analyses of liraglutide 3.0 mg for weight management

AIMS: Liraglutide 3.0 mg, an acylated GLP‐1 analogue approved for weight management, lowers body weight through decreased energy intake. We conducted exposure‐response analyses to provide important information on individual responses to given drug doses, reflecting inter‐individual variations in dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., le Roux, C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069568/
https://www.ncbi.nlm.nih.gov/pubmed/26833744
http://dx.doi.org/10.1111/dom.12639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069568/
https://www.ncbi.nlm.nih.gov/pubmed/26833744
http://dx.doi.org/10.1111/dom.12639

Ejemplares similares